| Name | Title | Contact Details |
|---|
Southside Medical Center is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities surrounding diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, kidney function, residual insulin, and presence of steroids.
linatech is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The CVMC Care Team is over 600 members strong, with nearly 40 active medical staff professionals and approximately 100 courtesy, consulting and Emergency Department staff members. 19 areas of medical specialization are currently represented through the state-of-the-art 248-bed facility, with plans for added services on the horizon. As an independent, non-profit hospital, CVMC is solely focused on delivering the highest quality of health care to Sylacauga and its surrounding communities.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.